If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  Temperature-Based Therapy For Prostate Cancer May Be Viable Treatment BEAVER CREEK, CO -- February 2, 1998 -- New data on the success of temperature-based technology treatments for prostate cancer was presented yesterday at an international prostate cancer conference in Beaver Creek, revealing that temperature-monitored freezing of cancerous tissue may be a viable, minimally-invasive method of successfully ridding the body of cancer. Douglas Chinn, M.D. of Southern California's Alhambra Hospital, revealed newly-compiled data on results for temperature-based technology treatments utilising state-of-the-art temperature monitoring. The data was highlighted by the announcement that more than 96 percent of Dr. Chinn's patients who received monitored temperature-based treatment for prostate cancer over the past three years remain cancer-free (as determined by negative biopsy results). In addition, Dr. Chinn announced that the PSA rates among patients receiving temperature monitored treatment were undetectable and that the incontinence rate was less than one percent. The temperature-based technology was developed by Irvine, California-based Endocare, Inc. Cancer of the prostate is the second most common malignancy in men and the third most common cause of death. In the U.S., the disease afflicts approximately five million men, representing nearly $5 billion in annual medical treatment costs. Dr. Chinn's data was heralded at the conference as a major blow against prostate cancer. It also follows news of Endocare's recent announcement of a specific labelling clearance by the FDA for Targeted Ablation Therapy -- utilising similar, minimally invasive tumour-freezing technology to remove breast tumours. Endocare is initiating clinical studies in the women's health arena.
|
